Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Central Nervous System Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
52 drugs · 206 active trials
5 drugs · 33 active trials
5 drugs · 185 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 22 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lenvatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Feb 12, 2019 |
| Nimotuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2007-10 |
| O6-Benzylguanine | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2002-10 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | Oct 1, 2017 |
| Aldesleukin | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2010-05 |
| Procarbazine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Dec 8, 2014 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Dec 17, 2012 |
| Alisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | May 14, 2014 |
| Bendamustine | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2008-10 |
| Camrelizumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Feb 13, 2020 |
| FACT Complex-targeting Curaxin CBL0137 | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2013-07 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jan 4, 2019 |
| Ruxolitinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jun 5, 2018 |
| Samotolisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Feb 15, 2022 |
| Vemurafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Adebrelimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 1, 2026 |
| Adjuvant Chemotherapy | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 3, 2021 |
| Cobimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 15, 2017 |
| Daratumumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 3, 2022 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 6, 2025 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 13, 2018 |
| Ipilimumab/Nivolumab Regimen | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 9, 2023 |
| Neratinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 9, 2017 |
| Panitumumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | May 16, 2018 |
| Selumetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 31, 2017 |
| Tafasitamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 8, 2022 |
| Tarlatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 8, 2025 |
| Tovorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2026-11 |
| Verteporfin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 15, 2021 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 12 | 0 | — | — | 2001-05 |
| Erlotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2003-07 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2001-12 |
| Panobinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2009-03 |
| Sonidegib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2009-03 |
| Avelumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | Mar 17, 2017 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2011-09 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2001-03 |
| Imiquimod | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2010-09 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2004-12 |
| Adavosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Sep 3, 2013 |
| Axitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2011-08 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2004-10 |
| Oxaliplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2000-12 |
| Plerixafor | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Feb 25, 2009 |
| Sirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2008-10 |
| Sorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2007-04 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2001-03 |
| Bimiralisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2015-07 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-02 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.